Menu
Search
|

Menu

Close
X

Aileron Therapeutics Inc ALRN.OQ (NASDAQ Stock Exchange Global Market)

2.17 USD
-- (--)
As of Nov 16
chart
Previous Close 2.17
Open --
Volume --
3m Avg Volume 23,470
Today’s High --
Today’s Low --
52 Week High 12.70
52 Week Low 1.77
Shares Outstanding (mil) 14.71
Market Capitalization (mil) 214.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.664
FY17
-1.539
FY16
-1.237
FY15
-0.445
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
--
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

Jeffrey Bailey
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Manuel Aivado
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Evan Lippman
Chief Financial Officer and Business Officer, Senior Vice President, Since 2015
Salary: --
Bonus: --
D. Allen Annis
Senior Vice President - Research, Since 2018
Salary: --
Bonus: --
Vojislav Vukovic
Chief Medical Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

490 Arsenal Way
WATERTOWN   MA   02472-2870

Phone: +1617.9950900

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

SPONSORED STORIES